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1 |  INTRODUCTION
Gestational trophoblastic disease (GTD) is a spectrum of cel-
lular proliferations arising from the placental villous tropho-
blast.1 It encompasses three premalignant conditions: partial 
hydatidiform mole (PHM), complete hydatidiform mole 
(CHM), and atypical placental site nodule. Moreover, GTD 
can progress to three malignant gestational trophoblastic neo-
plasias (GTN). GTN are classified histologically into three 
distinct subgroups: invasive mole, choriocarcinoma (CC), 
and the very rare placental site trophoblastic tumor (PSTT)/
epithelioid trophoblastic tumor (ETT).2,3 (Figure 1).
Hydatidiform mole incidence is of 1 in 591 pregnancies 
and 1 in 714 live births in the developed world. The two most 
important risk factors for the development of a molar preg-
nancy are age and history of previous pregnancies. Extreme 
maternal age significantly increases the risk of developing 
a molar pregnancy, especially complete mole. The risk also 
increases in women over 40 years old, being 7‐8 times greater 
than in women between 20 and 35  years old.4 The risk of 
developing a new molar pregnancy increases from 1%‐2% in 
patients with one previous mole, to 15%‐20% in patients with 
two previous molar pregnancies.5
Invasive mole diagnosis is based on the presence of a hy-
datidiform mole with myometrial, blood or lymphatic inva-
sion or the presence of distant metastases and an abnormal 
HCG regression. The progression of a hydatidiform mole to 
an invasive mole is about 10%‐17%, being more frequent in 
the case of complete mole.4
The most frequent clinical presentation of invasive mole 
includes persistent or heavy vaginal bleeding after evacuation 
of molar pregnancy. When invasive mole is either suspected 
or confirmed histopathologically, to perform a thoracoab-
dominopelvic CT and cerebral MRI is mandatory. In rare 
cases, metastases occurred most frequently in the following 
sites: the lung (80%) followed by the vagina (30%), the liver 
(10%), and the brain (10%).6
Chemotherapy is the primary treatment of choice for in-
vasive mole. FIGO prognostic scoring system determines 
the risk of resistance to methotrexate. The regimen for the 
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Abstract
Gestational trophoblastic disease can result in serious complications and disease pro-
gression. Therefore, follow‐up of such patients is essential for early detection of 
malignant trophoblastic tumors and to reduce mortality rate. Primary treatment is 
chemotherapy but hysterectomy should be considered in patients who have uncon-
trollable hemorrhage and hemodynamic instability.
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low‐risk patients (FIGO score < 7) is methotrexate 50 mg IM 
on days 1, 3, 5, and 7 alternated with folates 15 mg PO on 
days 2, 4, and 6. In patients with poor response to methotrex-
ate (serum and BHCH increase or plateau), actinomycin D 
should be added or multidrug therapy, which has a complete 
remission rate close to 100%. In high‐risk patients (FIGO 
score ≥ 7) the polychemotherapeutic treatment according to 
the EMA‐CO regimen (Etoposide + Metotrexate + Actinom
ycin D alternating with Cyclophosphamide  +  Vincristine) 
is the preferred option. BHCG remission and normalization 
with the EMA‐CO regimen is 98%. In case of poor response 
to this treatment, EMA‐EP or BEP (Bleomycin + Etoposide 
+ Cisplatin) should be considered.7,8 In WHO score system, 
risk score (5‐6) and clinicopathologic diagnosis of choriocar-
cinoma are both associated with an increased risk of resis-
tance to single‐agent chemotherapy. Lowering the threshold 
for the use of multiple‐agent chemotherapy in these other-
wise low‐risk patients can be considered.2
Finally, if myometrial invasion is suspected, uterine cu-
rettage and endometrial biopsy are contraindicated7 due to 
the risk of uterine perforation. The surgical resection of me-
tastases in high‐risk patients is not recommended, save in the 
case of residual lesions in patients resistant to chemotherapy. 
Biopsy of metastases is not recommended due to the risk of 
hemorrhage.8
The risk of recurrence of chemotherapy‐treated tropho-
blastic disease is 3%.8 Therefore, a follow‐up of at least 
12  months with BHCG monthly determination is recom-
mended, starting from the first two consecutive BHCG neg-
ative weeks.7,8 Hormonal contraception is indicated during 
this period.7
2 |  CASE PRESENTATION
A 53‐year‐old woman, with an obstetric history of 7 preg-
nancies (5 vaginal births and 2 abortions) with the last date 
of menstruation 6  months ago. She was presented to the 
hospital with severe vaginal bleeding and abdominal pain. 
Days before, she had suffered an episode of hematemesis and 
epigastralgia, and she was assessed by the Gastrointestinal 
Department, who performed a gastroscopy with normal biop-
sies, and the endoscopic exploration showed erosive lesions 
in relation to NSAID. On gynecologic examination, there 
were no vulvar, vaginal, or cervical lesions, and an enlarged 
uterus was noted. An abdominal ultrasonography (Figure 2) 
and thoracoabdominopelvic CT scan (Figure 3) were per-
formed, demonstrating a pelvic mass of 14 cm suggestive of 
trophoblastic disease and two nonspecific millimetric pulmo-
nary nodules.
Transvaginal ultrasound showed an enlarged uterus with 
an intracavitary heterogeneous vacuolar image. BHCG was 
F I G U R E  1  Gestational trophoblastic 
disease spectrum
F I G U R E  2  Abdominopelvic US: Vesicular pattern of multiple 
echoes
F I G U R E  3  Thoracoabdominopelvic CT scan: Pelvic mass of 
14 cm
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684 180 mIU/mL. Suspecting GTD, uterine curettage aspira-
tion was performed and confirmed the histological diagnosis 
of complete mole (Figures 4 and 5).
Follow‐up monitoring BHCG was decided. One week 
after surgical evacuation, the patient reported abundant 
vaginal bleeding with a BHCG plateau of 14 000 mUI/mL. 
On gynecologic examination there were no vulvar, vaginal, 
or cervical lesions. The transvaginal ultrasound showed an 
irregular intracavitary image of 46 × 30 mm with positive 
vascularization suggesting myometrial invasion. Moreover, 
an increase in BHCG to 19  453  mIU/mL was detected. 
An urgent hysterectomy (Figure 6) was performed due to 
uncontrollable vaginal bleeding resulting in the patient 
being hemodynamically unstable with a blood pressure of 
85/50 mm Hg, pulse rate of 120 bpm, hemoglobin: 7.2 g/
dL, hematocrit: 22%, and transfusion of 2 units of packed 
red blood cells.
Subsequently, the presence of myometrial invasion was 
confirmed histologically (Figures 7 and 8).
On the first day of admission, a thoracoabdominopelvic 
CT scan was requested, finding new bilateral pulmonary nod-
ules suspected to be metastases (Figure 9). The brain MRI 
was normal.
Seven days after hysterectomy (fourteen days postmo-
lar evacuation), she came back to the emergency room due 
to an increase in vaginal bleeding. A bleeding mucosal 
vaginal lesion of 2  cm suggested vaginal metastasis lo-
cated in the paraurethral region adjacent to the introitus 
(Figure 10).
With a diagnosis of an invasive mole with pulmo-
nary and vaginal spread, the patient was referred to the 
Oncology Department. The patient began chemotherapy 
F I G U R E  4  Uterine curettage aspiration
F I G U R E  5  Complete hydatidiform mole. Diffuse villous 
enlargement cistern formation, hydropic changes, and trophoblastic 
hyperplasia
F I G U R E  6  Piece of hysterectomy: Intracavitary persistent 
gestational trophoblastic tissue. Intramyometrial vesicles invasion 
(arrow)
F I G U R E  7  Invasive complete hydatidiform mole. Molar villi 
within the myometrium
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with EMA‐CO (Etoposide  +  Methotrexate  +  Actinomyc
in‐Oncovin  +  Cyclophosphamide). After the third cycle, a 
significant decrease in BHCG with complete response of pul-
monary and vaginal metastatic disease was achieved.
In summary, an initially bad prognosis with an extended 
metastatic disease reached a complete and stable response 
(Figure 11).
3 |  DISCUSSION
Hydatidiform mole is a benign tumor with malignant poten-
tial. Progression occurs in 15% of complete mole and 1.5% 
of partial mole.9 Moreover, term pregnancies carry a greater 
risk of progression than spontaneous abortion or a previous 
mole.5 In our case, the invasive mole progressed after the 
evacuation of a complete mole and previous obstetric history 
of 5 term pregnancies.
The classical medical presentation of GTD has decreased 
due to the early diagnosis in the screening in the first trimes-
ter. However, the risk of developing postmolar GTN remains 
without changes.10
Spontaneous presentation of an invasive mole is ex-
tremely rare. It is preceded by a hydatidiform mole in about 
95% of cases with an interval of less than 6 months between 
the presentation of the case and the diagnosis of invasive 
mole. In our case, the progression to invasive mole was 
within 2 months from the evacuation of the complete mole. 
Follow‐up of such patients is essential for early detection 
of malignant trophoblastic tumors and to reduce mortality 
rate.11
F I G U R E  8  Detail of vascular invasion
F I G U R E  9  Thoracoabdominopelvic CT scan: Pulmonary 
nodules of 1.44 cm and 1.75 cm suggestive of pulmonary metastases
(A)
(B)
F I G U R E  1 0  Vaginal metastases
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Invasive mole usually occurs in women of reproductive 
age and is extremely rare in perimenopausal women. Only 5 
cases of hydatidiform mole in postmenopausal women have 
been reported in literature since 2004.12 The pathogenesis 
of invasive mole in perimenopausal women is unclear, but it 
is believed that it may be due to immature spontaneous ovu-
lation of oocytes leading to decreased fertility in perimeno-
pausal patients and eventually to postmenopausal patients.
The most common locations for invasive mole metastases 
are the vagina, lungs, and brain, due to the invasion of molar 
tissue into the venous system. Other sites of metastases, includ-
ing the epidural space and bladder, have been rarely reported.13
Seckl et al6 in 2000, locally invasive gestational tropho-
blastic neoplasia develops in 15% of patients and metastatic 
form in 4% of patients after evacuation of complete mole and 
infrequently after partial mole. In our case, metastases oc-
curred in lungs and vagina, making an unusual presentation 
of invasive mole. Moreover, biopsy of metastasis is not rec-
ommended due to the risk of hemorrhage.7
Medical therapy is the best option and histological di-
agnosis is not mandatory for chemotherapy initiation. The 
diagnosis is confirmed using diagnostic imaging and serum 
BHCG.7
Hysterectomy may be required in cases of uncontrolled 
vaginal or intra‐abdominal bleeding (another option is the 
embolization of uterine vessels,2 but this is only considered 
if the patient is hemodynamically stable), resistance to che-
motherapy or neoplastic gestational diseases. Surgical op-
tions could be a valid first‐line therapy mainly in women 
who do not wish to retain fertility, but it does not prevent the 
appearance of metastases.14 In our case, a hysterectomy was 
performed due to the life‐threatening hemorrhage and hemo-
dynamic instability. However, it did not prevent the later ap-
pearance of the vaginal metastases.
Finally, in patients with an extended uterine tumor, hys-
terectomy could substantially reduce trophoblastic tumor 
burden and the number of chemotherapy cycles, thus reduc-
ing their toxicity.14 The final diagnosis of our patient was an 
invasive mole that progressed from a complete hydatidiform 
mole to eventual pulmonary and vaginal metastases. The pa-
tient is therefore classified as high risk (III:8) according to 
the FIGO staging system and WHO risk factor scoring (2) 
(FIGO III: disease in the lung. FIGO score 8: Age > 40 = 1 
point; Antecedent pregnancy: mole = 0 point; Interval from 
mole and invasive mole: <4 months = 0 point; BHCG pre-
treatment = >105 = 684 180 mIU/mL = 4 points; Largest 
tumor including uterus > 5 cm (14 cm) = 2 points; Number 
of metastases identified: 3 (2 lungs and 1 vagina) = 1 point; 
Site of metastases: Lungs = 0 points; Tables 1 and 2) with 
a favorable clinical response to the established surgical and 
chemotherapy treatment. Our patient's serum BHCG levels 
gradually decreased to within normal range with the third 
cycle of chemotherapy; two additional cycles were given in 
order to reduce the risk of relapse. On the latest follow‐up, 
no evidence of disease has been observed after 18 months of 
completing chemotherapy.
We believe that our case will contribute to the literature 
with respect to the early detection of invasive moles and their 
complications. Although the first line of treatment is che-
motherapy, we must consider the surgical option in patients 
who have uncontrollable hemorrhage and hemodynamic 
instability.
F I G U R E  1 1  Chronological 
explanation of events
FIGO stage Description
I Gestational trophoblastic tumors strictly confined to 
the uterine corpus
II Gestational trophoblastic tumors extending to the 
adnexa or to the vagina, but limited to the genital 
structures
III Gestational trophoblastic tumors extending to the 
lungs, with or without genital tract involvement
IV All other metastatic sites
T A B L E  1  FIGO staging and 
classification for gestational trophoblastic 
neoplasia
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T A B L E  2  WHO scoring system based on prognostic factors
WHO risk factor scoring with FIGO 
staging 0 1 2 4
Age <40 >40 – –
Antecedent pregnancy Mole Abortion Term  
Interval from index pregnancy, mo <4 4‐6 7‐12 >12
Pretreatment hCG mIU/mL <103 >103‐104 >104‐105 >105
Largest tumor size including uterus, cm – 3‐4 ≥5 –
Site of metastases including uterus Lung Spleen, kidney Gastrointestinal tract Brain, liver
Number of metastases identified – 1‐4 5‐8 >8
Previous failed chemotherapy – – Single drug Two or more drugs
